PsoriasisDiabetes Mellitus, Type 1Diabetes MellitusDiabetes Mellitus, Type 2Diabetes ComplicationsDermatologic AgentsDiabetes Mellitus, ExperimentalArthritis, PsoriaticPUVA TherapyUltraviolet TherapyDiabetes, GestationalBlood GlucoseHemoglobin A, GlycosylatedHypoglycemic AgentsCoal TarHLA-C AntigensSkinInsulinAcitretinRisk FactorsAnthralinKeratolytic AgentsDiabetes InsipidusKeratinocytesSeverity of Illness IndexGenetic Predisposition to DiseaseHyperglycemiaNail DiseasesClobetasolCase-Control StudiesDermatologyEpidermisPhototherapyPrevalenceGlucose Tolerance TestCohort StudiesDiabetic NephropathiesIslets of LangerhansObesityPrediabetic StateDiabetic RetinopathyInsulin ResistanceInsulin-Secreting CellsScalp DermatosesMice, Inbred NODInterleukin-23IncidenceTreatment OutcomeDermatitis, AtopicDiabetic NeuropathiesAge of OnsetStreptozocinSkin DiseasesBlood Glucose Self-MonitoringCardiovascular DiseasesPregnancy in DiabeticsBody Mass IndexProspective StudiesCross-Sectional StudiesAdministration, TopicalPolymorphism, Single NucleotideDermatitis